US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
US8143283B1
(en)
*
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US6805865B1
(en)
|
1993-05-27 |
2004-10-19 |
Entremed, Inc. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
US20040248799A1
(en)
*
|
1993-05-27 |
2004-12-09 |
Holaday John W. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
DE4422237A1
(de)
|
1994-06-24 |
1996-01-04 |
Gruenenthal Gmbh |
Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6358735B1
(en)
|
1995-06-30 |
2002-03-19 |
University Of Kansas Medical Center |
Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
|
US6440729B1
(en)
|
1995-06-30 |
2002-08-27 |
University Of Kansas Medical Center |
Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
JP3263598B2
(ja)
*
|
1995-11-01 |
2002-03-04 |
有限会社ドット |
経鼻吸収用生理活性ペプチド組成物
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
DK2177517T3
(da)
*
|
1996-07-24 |
2011-11-21 |
Celgene Corp |
Aminosubstitueret 2-(2,6-dioxopiperidin-3-yl)-phthalimid til at nedsætte TNF-alfa-niveauer
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US5798368A
(en)
*
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
CZ295762B6
(cs)
*
|
1996-07-24 |
2005-10-12 |
Celgene Corporation |
2,6-Dioxopiperidiny, jejich soli a optické izomery, farmaceutické kompozice obsahující tyto sloučeniny a léčiva pro snížení hladiny TNFalfa obsahující tyto sloučeniny
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US5955496A
(en)
*
|
1996-08-13 |
1999-09-21 |
The Regents Of The University Of California |
Dihydroxy-oxy-eicosadienoates
|
ATE493983T1
(de)
*
|
1996-11-05 |
2011-01-15 |
Childrens Medical Center |
Thalidomide und dexamethason für die behandlung von tumors
|
US6670337B1
(en)
|
1998-01-29 |
2003-12-30 |
Yeda Reaearch And Development Co., Ltd. |
Facilitation of wound healing with CM101/GBS toxin
|
US6028060A
(en)
*
|
1997-01-29 |
2000-02-22 |
Vanderbilt University |
Treatment of chronic inflammatory diseases with CM101/GBS toxin
|
US5981508A
(en)
|
1997-01-29 |
1999-11-09 |
Vanderbilt University |
Facilitation of repair of neural injury with CM101/GBS toxin
|
US5858991A
(en)
*
|
1997-01-29 |
1999-01-12 |
Vanderbilt University |
Facilitation of wound healing with CM101/GBS toxin
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
US5994388A
(en)
*
|
1997-03-18 |
1999-11-30 |
The Children's Medical Center Corporation |
Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
|
US6265388B1
(en)
|
1997-03-21 |
2001-07-24 |
President And Fellows Of Harvard College |
Antisense inhibition of angiogenin expression
|
US6174695B1
(en)
|
1997-08-12 |
2001-01-16 |
The Regents Of The University Of California |
Epoxide hydrolase inhibitor methods
|
US6638949B1
(en)
|
1997-08-25 |
2003-10-28 |
Judah Folkman |
Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
SK7382000A3
(en)
*
|
1997-11-18 |
2000-12-11 |
Celgene Corp |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use
|
DK1064277T3
(da)
*
|
1998-03-16 |
2005-10-17 |
Celgene Corp |
2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner
|
JP2002514578A
(ja)
*
|
1998-05-11 |
2002-05-21 |
エントレメッド インコーポレイテッド |
2−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
WO1999058126A1
(en)
|
1998-05-11 |
1999-11-18 |
The Endowment For Research In Human Biology, Inc. |
Use of neomycin for treating angiogenesis-related diseases
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
US8197430B1
(en)
*
|
1998-05-22 |
2012-06-12 |
Biopheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US8609614B2
(en)
|
1998-07-22 |
2013-12-17 |
Vanderbilt University |
GBS toxin receptor compositions and methods of use
|
US6576613B1
(en)
*
|
1998-07-24 |
2003-06-10 |
Corvas International, Inc. |
Title inhibitors of urokinase
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
AU5991699A
(en)
|
1998-09-21 |
2000-04-10 |
Biochem Pharma Inc. |
Quinolizinones as integrin inhibitors
|
US6231889B1
(en)
*
|
1998-09-21 |
2001-05-15 |
Chronorx, Llc |
Unit dosage forms for the treatment of herpes simplex
|
US6596690B2
(en)
|
1998-10-06 |
2003-07-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vasostatin as marrow protectant
|
FR2784580B1
(fr)
*
|
1998-10-16 |
2004-06-25 |
Biosepra Inc |
Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US7238711B1
(en)
*
|
1999-03-17 |
2007-07-03 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
WO2000041547A2
(en)
*
|
1999-01-13 |
2000-07-20 |
The Rockefeller University |
Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
|
ES2250121T3
(es)
*
|
1999-03-18 |
2006-04-16 |
Celgene Corporation |
1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
|
DK1040838T3
(da)
|
1999-03-31 |
2003-05-26 |
Gruenenthal Gmbh |
Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6468990B1
(en)
*
|
1999-05-17 |
2002-10-22 |
Queen's University At Kingston |
Method of inhibiting binding of nerve growth factor to p75 NTR receptor
|
US6673843B2
(en)
*
|
1999-06-30 |
2004-01-06 |
Emory University |
Curcumin and curcuminoid inhibition of angiogenesis
|
US6916843B1
(en)
*
|
1999-08-11 |
2005-07-12 |
The United States Of America As Represented By The Department Of Health And Human Services |
Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
|
US7087592B1
(en)
|
1999-08-23 |
2006-08-08 |
Entre Med, Inc. |
Compositions comprising purified 2-methoxyestradiol and methods of producing same
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
EP1227843B1
(en)
|
1999-11-10 |
2009-10-14 |
BioPheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US6204270B1
(en)
*
|
1999-11-12 |
2001-03-20 |
Eyal S. Ron |
Ophthalmic and mucosal preparations
|
CA2387805C
(en)
|
1999-11-18 |
2012-08-28 |
Corvas International, Inc. |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
US6379708B1
(en)
*
|
1999-11-20 |
2002-04-30 |
Cytologic, Llc |
Method for enhancing immune responses in mammals
|
AU4515001A
(en)
*
|
1999-12-02 |
2001-06-18 |
Regents Of The University Of Michigan, The |
Compositions and methods for locally treating inflammatory diseases
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
CN1121218C
(zh)
*
|
2000-03-08 |
2003-09-17 |
台湾东洋药品工业股份有限公司 |
酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用
|
KR100872884B1
(ko)
*
|
2000-03-24 |
2008-12-10 |
바이오스피어 메디칼 인코포레이티드 |
능동 색전화용 미소구
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
AU2001249755A1
(en)
*
|
2000-03-31 |
2001-10-15 |
Celgene Corporation |
Inhibition of cyclooxygenase-2 activity
|
ES2258084T3
(es)
|
2000-05-15 |
2006-08-16 |
Celgene Corporation |
Composiciones para el tratamiento de cancer que comprenden un inhibidor de topoisomerasa y talidomida.
|
ES2261415T3
(es)
*
|
2000-05-15 |
2006-11-16 |
Celgene Corporation |
Composiciones para el tratamiento de cancer colorrectal que comprenden talidomida e irinotecan.
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
US20040121945A1
(en)
*
|
2000-12-15 |
2004-06-24 |
Hong Liang |
Compositions and methods for inhibiting endothelial cell proliferation
|
EP1226824A1
(en)
*
|
2001-01-24 |
2002-07-31 |
TTY Biopharm Company Limited |
Use of thalidomide for the treatment of hepatocellular carcinoma
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
US7320991B2
(en)
*
|
2001-02-27 |
2008-01-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Analogs of thalidomide as potential angiogenesis inhibitors
|
AU2002257195A1
(en)
*
|
2001-04-23 |
2002-11-05 |
University Of Virginia Patent Foundation |
Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
|
US7122517B2
(en)
*
|
2001-07-27 |
2006-10-17 |
Kansas University Medical Center |
Crystallized structure of type IV collagen NC1 domain hexamer
|
DE60231989D1
(de)
*
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
GB0125659D0
(en)
*
|
2001-10-25 |
2001-12-19 |
Ssl Int Plc |
Spermicides
|
WO2003044179A2
(en)
*
|
2001-11-20 |
2003-05-30 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US20030139469A1
(en)
*
|
2002-01-23 |
2003-07-24 |
The Regents Of The University Of California |
Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
|
WO2003075847A2
(en)
*
|
2002-03-08 |
2003-09-18 |
Emory University |
NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
|
WO2003075860A2
(en)
*
|
2002-03-08 |
2003-09-18 |
Abgent, Inc. |
Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
|
AU2003220685A1
(en)
*
|
2002-04-09 |
2003-10-27 |
Greenville Hospital System |
Metastasis modulating activity of highly sulfated oligosaccharides
|
NZ572388A
(en)
|
2002-05-17 |
2010-05-28 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
EP1536813A4
(en)
*
|
2002-06-26 |
2005-11-09 |
Entremed Inc |
COMPOSITIONS AND METHODS FOR PROTEIN-ACTIVATED RECEPTOR ANTAGONISTS
|
MX337052B
(es)
|
2002-07-15 |
2016-02-11 |
Univ Texas |
Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
|
AU2003254120B2
(en)
*
|
2002-07-22 |
2009-09-10 |
Teva Pharamceuticals International Gmbh |
Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
|
GEP20074270B
(en)
*
|
2002-07-23 |
2007-12-25 |
Univ Michigan |
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
BR0315316A
(pt)
*
|
2002-10-15 |
2005-08-16 |
Celgene Corp |
Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
NZ540186A
(en)
*
|
2002-10-31 |
2008-03-28 |
Celgene Corp |
Composition for the treatment of macular degeneration
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7354948B2
(en)
|
2002-11-06 |
2008-04-08 |
Celgene Corporation |
Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
JP2006512318A
(ja)
*
|
2002-11-12 |
2006-04-13 |
アルコン,インコーポレイテッド |
眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
|
US7230012B2
(en)
*
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
US9006267B2
(en)
*
|
2002-11-14 |
2015-04-14 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
US8431396B2
(en)
|
2003-03-21 |
2013-04-30 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
US7196093B2
(en)
*
|
2003-04-09 |
2007-03-27 |
General Atomics |
Reversible inhibitors of SAH hydrolase and uses thereof
|
US7517887B2
(en)
*
|
2003-04-09 |
2009-04-14 |
General Atomics |
Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
|
US7868011B2
(en)
*
|
2003-04-09 |
2011-01-11 |
General Atomics |
Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
|
DE10323898A1
(de)
|
2003-05-26 |
2004-12-23 |
Wilex Ag |
Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
|
JP2006526025A
(ja)
*
|
2003-05-28 |
2006-11-16 |
エントレメッド インコーポレイテッド |
抗血管新生剤
|
WO2005016326A2
(en)
*
|
2003-07-11 |
2005-02-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
PL1648998T3
(pl)
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
EP1663223B1
(en)
*
|
2003-09-17 |
2014-01-01 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Thalidomide analogs as tnf-alpha modulators
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
AU2003286931A1
(en)
*
|
2003-11-06 |
2004-06-06 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
US20070208057A1
(en)
|
2003-11-06 |
2007-09-06 |
Zeldis Jerome B |
Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
|
US20050143420A1
(en)
*
|
2003-12-02 |
2005-06-30 |
Moutouh-De Parseval Laure |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
US7430276B2
(en)
*
|
2004-02-25 |
2008-09-30 |
Nanodynamics-88 |
Low dose X-ray mammography method
|
JP2007529426A
(ja)
*
|
2004-03-12 |
2007-10-25 |
エントレメッド インコーポレイテッド |
抗血管新生薬
|
CN1956718A
(zh)
*
|
2004-03-22 |
2007-05-02 |
细胞基因公司 |
用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
JP2007532641A
(ja)
*
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
|
WO2005102333A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
|
US20050239842A1
(en)
*
|
2004-04-23 |
2005-10-27 |
Zeldis Jerome B |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
PT1949915E
(pt)
*
|
2004-04-30 |
2012-11-27 |
Biopheresis Technologies Inc |
Método e sistema para remover rfnt1,rfnt2, e ril2 solúveis em pacientes
|
US7273890B1
(en)
*
|
2004-06-08 |
2007-09-25 |
Sagittarius Life Science Corp. |
ST104P, an anti-angiogenic agent
|
US20060063930A1
(en)
*
|
2004-08-20 |
2006-03-23 |
Agoston Gregory E |
Compositions and methods comprising proteinase activated receptor antagonists
|
BRPI0514865A
(pt)
*
|
2004-09-03 |
2008-06-24 |
Celgene Corp |
processo para preparar um composto
|
CN101309585A
(zh)
*
|
2004-10-28 |
2008-11-19 |
细胞基因公司 |
使用pde4调节剂治疗和控制中枢神经系统损伤的方法和组合物
|
CN101102771A
(zh)
*
|
2004-11-23 |
2008-01-09 |
细胞基因公司 |
用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
|
CA2607228C
(en)
*
|
2005-05-09 |
2014-09-16 |
Biosphere Medical S.A. |
Compositions and methods using microspheres and non-ionic contrast agents
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20080167272A1
(en)
*
|
2005-06-16 |
2008-07-10 |
Auckland Uniservices Limited |
Thalidomide metabolites and methods of use
|
ES2402204T3
(es)
|
2005-06-30 |
2013-04-29 |
Celgene Corporation |
Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
|
EP1909796A4
(en)
*
|
2005-07-12 |
2009-11-11 |
Univ California |
USE OF CIS-EPOXYICICATURATOIC ACIDS AND SOLUBLE HYDROLASE EPOXY INHIBITORS TO ATTENUATE VIEW DISORDERS
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070065514A1
(en)
*
|
2005-09-22 |
2007-03-22 |
Howell Mark D |
Method for enhancing immune responses in mammals
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
KR20110010813A
(ko)
*
|
2005-10-14 |
2011-02-07 |
에프. 호프만-라 로슈 아게 |
5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-b][1,4] 벤조디아제핀의 투여 섭생
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
EP2368581B1
(en)
*
|
2006-01-30 |
2018-08-29 |
Biosphere Medical, Inc. |
Porous intravascular embolization particles and related methods
|
US20080033366A1
(en)
*
|
2006-01-30 |
2008-02-07 |
Surgica Corporation |
Compressible intravascular embolization particles and related methods and delivery systems
|
WO2007109312A2
(en)
*
|
2006-03-20 |
2007-09-27 |
Entremed, Inc. |
Disease modifying anti-arthritic activity of 2-methoxyestradiol
|
US20070226632A1
(en)
*
|
2006-03-21 |
2007-09-27 |
Nokia Corporation |
Method, electronic device and computer program product for enhancing contact list functionality
|
EP2004614B1
(en)
*
|
2006-04-13 |
2016-10-19 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Tetrahalogenated compounds useful as inhibitors of angiogenesis
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
US20080051431A1
(en)
*
|
2006-05-26 |
2008-02-28 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds in combination therapy
|
RU2426542C2
(ru)
*
|
2006-05-26 |
2011-08-20 |
Селджин Корпорейшн |
Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении
|
WO2008007979A1
(en)
*
|
2006-07-12 |
2008-01-17 |
Auckland Uniservices Limited |
(2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
EP2068877A4
(en)
|
2006-07-19 |
2011-09-21 |
Cleveland Clinic Foundation |
COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
CN101138634A
(zh)
|
2006-09-07 |
2008-03-12 |
于保法 |
用于治疗肿瘤的组合物
|
US20080075690A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Mark Douglas Howell |
Method for enhancing immune responses in mammals
|
MX2009008531A
(es)
|
2007-02-16 |
2009-08-26 |
Amgen Inc |
Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
|
KR101506607B1
(ko)
*
|
2007-04-13 |
2015-03-30 |
켐제닉스 파마슈티칼스 인크. |
세팔로탁신 경구 제형
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
AU2008298592A1
(en)
|
2007-09-14 |
2009-03-19 |
Nitto Denko Corporation |
Drug carriers
|
RU2510270C2
(ru)
*
|
2007-09-26 |
2014-03-27 |
Индиана Юниверсити Рисёч Энд Текнолоджи Корпорейшн |
Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза
|
US11331294B2
(en)
|
2007-09-26 |
2022-05-17 |
Indiana University Research And Technology Corporation |
Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
|
BRPI0820298A8
(pt)
|
2007-11-09 |
2018-05-08 |
Affitech Res As |
composições e métodos de anticorpos anti-vegf
|
US20090137631A1
(en)
*
|
2007-11-22 |
2009-05-28 |
National Yang-Ming University |
Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
|
JP2011526892A
(ja)
|
2008-06-30 |
2011-10-20 |
アンジオブラスト システムズ,インコーポレーテッド |
併用療法を使用した眼疾患及び過剰血管新生の治療
|
EP2323679A4
(en)
|
2008-07-25 |
2012-08-22 |
Univ Colorado |
CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION
|
WO2010062678A2
(en)
*
|
2008-10-30 |
2010-06-03 |
David Liu |
Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
|
CN105640918A
(zh)
|
2009-05-19 |
2016-06-08 |
细胞基因公司 |
4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮的制剂
|
US20120134969A1
(en)
|
2009-05-25 |
2012-05-31 |
Hiroshi Handa |
Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
|
GB0914330D0
(en)
|
2009-08-17 |
2009-09-30 |
Univ Dublin City |
A method of predicting response to thalidomide in multiple myeloma patients
|
US20120183546A1
(en)
|
2009-09-23 |
2012-07-19 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
US9056923B2
(en)
|
2010-12-10 |
2015-06-16 |
The Johns Hopkins University |
Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
EP2702410A2
(en)
|
2011-04-29 |
2014-03-05 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
CA2840212A1
(en)
|
2011-06-29 |
2013-01-03 |
Amgen Inc. |
Predictive biomarker of survival in the treatment of renal cell carcinoma
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
US20130058926A1
(en)
*
|
2011-08-30 |
2013-03-07 |
Shiseido Company, Ltd. |
Method for alleviating and/or preventing skin reddening
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
JP6185490B2
(ja)
|
2012-02-21 |
2017-08-23 |
セルジーン コーポレイション |
3−(4−ニトロ−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンの固体形態
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CA2877736C
(en)
*
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
WO2014124280A1
(en)
|
2013-02-08 |
2014-08-14 |
Institute For Myeloma & Bone Cancer Research |
Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
|
DK2956183T3
(da)
|
2013-02-13 |
2021-06-14 |
Cartiheal 2009 Ltd |
Faste substrater til fremme af celle og væv vækst
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
US9198898B2
(en)
|
2013-06-24 |
2015-12-01 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
US8906951B1
(en)
|
2013-06-24 |
2014-12-09 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
WO2015116802A1
(en)
|
2014-01-29 |
2015-08-06 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
WO2015184087A2
(en)
|
2014-05-28 |
2015-12-03 |
Institute For Myeloma & Bone Cancer Research |
Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
|
JP6640126B2
(ja)
|
2014-06-27 |
2020-02-05 |
セルジーン コーポレイション |
セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
PL3214081T3
(pl)
|
2014-10-30 |
2021-04-06 |
Kangpu Biopharmaceuticals, Ltd. |
Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
|
EP3223810A1
(en)
|
2014-11-26 |
2017-10-04 |
Baofa Yu |
Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
WO2016209972A1
(en)
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
SG10201913841SA
(en)
|
2015-07-24 |
2020-03-30 |
Oncotracker Inc |
Gamma secretase modulators for the treatment of immune system dysfunction
|
CA3000661C
(en)
*
|
2015-09-30 |
2024-04-02 |
Nigel H. Greig |
Thalidomide analogs and methods of use
|
SG10201912959QA
(en)
|
2015-10-21 |
2020-02-27 |
Otsuka Pharma Co Ltd |
Benzolactam compounds as protein kinase inhibitors
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
ES2898329T3
(es)
|
2016-01-12 |
2022-03-07 |
Oncotracker Inc |
Métodos mejorados para supervisar el estado inmunitario de un sujeto
|
CA3096270C
(en)
*
|
2016-03-31 |
2024-05-21 |
Omeros Corporation |
Methods for inhibiting angiogenesis in a subject in need thereof
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
EP4001269A1
(en)
|
2016-12-22 |
2022-05-25 |
Amgen Inc. |
Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
EP3576726A1
(en)
|
2017-02-06 |
2019-12-11 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
EP3618842B1
(en)
|
2017-05-01 |
2023-10-18 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
EP3639028A4
(en)
|
2017-06-13 |
2021-04-14 |
Inc. Onco Tracker |
DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MALIGNE SOLID TUMORS
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
WO2019210080A1
(en)
*
|
2018-04-25 |
2019-10-31 |
The Regents Of The University Of California |
Methods and compositions for skeletal and neurological disorders
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3807276A2
(en)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
CA3106239A1
(en)
|
2018-07-27 |
2020-01-30 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
JP2022512971A
(ja)
|
2018-11-08 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
処置およびt細胞調節のための方法および併用
|
AU2019381827A1
(en)
|
2018-11-16 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods of dosing engineered T cells for the treatment of B cell malignancies
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021006238A
(es)
|
2018-11-30 |
2021-10-01 |
Juno Therapeutics Inc |
Metodos para tratamiento que usan terapia celular adoptiva.
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
AU2019401495A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
US20220073504A1
(en)
|
2018-12-20 |
2022-03-10 |
Amgen Inc. |
Kif18a inhibitors
|
MA54863A
(fr)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
US11897930B2
(en)
|
2020-04-28 |
2024-02-13 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|